(XLV) Health Care Sector SPDR Fund - Ratings and Ratios
Pharmaceuticals, HealthCare, Equipment, Biotechnology, LifeSciences
Description: XLV Health Care Sector SPDR Fund
The Health Care Select Sector SPDR Fund (XLV) is an ETF that tracks a specific index, employing a replication strategy to invest at least 95% of its assets in the constituent securities. The fund focuses on the healthcare sector, covering various industries such as pharmaceuticals, health care equipment, providers, biotechnology, and life sciences.
From a sectoral perspective, XLV provides diversified exposure to the healthcare industry, which is known for its stability and growth potential. Key Performance Indicators (KPIs) to monitor for XLV include the sectors revenue growth, earnings yield, and dividend yield. The funds holdings are likely to be dominated by large-cap stocks, with a mix of established pharmaceutical companies and innovative biotech firms.
To further analyze XLV, one can examine its underlying holdings, looking at metrics such as the portfolios weighted average market capitalization, price-to-earnings (P/E) ratio, and return on equity (ROE). Additionally, monitoring the funds tracking error, expense ratio, and trading volume can provide insights into its operational efficiency and liquidity.
Given the current market landscape, a Trading Analyst should consider factors such as regulatory changes, patent expirations, and innovation trends in the healthcare sector when evaluating XLVs potential performance. By analyzing these factors and KPIs, one can form a more comprehensive view of the funds prospects and make informed investment decisions.
XLV ETF Overview
| Market Cap in USD | 33,643m |
| Category | Health |
| TER | 0.09% |
| IPO / Inception | 1998-12-16 |
XLV ETF Ratings
| Growth Rating | 9.0% |
| Fundamental | - |
| Dividend Rating | 58.5% |
| Return 12m vs S&P 500 | -23.9% |
| Analyst Rating | - |
XLV Dividends
| Dividend Yield 12m | 1.73% |
| Yield on Cost 5y | 2.49% |
| Annual Growth 5y | 6.31% |
| Payout Consistency | 96.1% |
| Payout Ratio | % |
XLV Growth Ratios
| Growth Correlation 3m | 36.8% |
| Growth Correlation 12m | -79.8% |
| Growth Correlation 5y | 85.6% |
| CAGR 5y | 7.54% |
| CAGR/Max DD 5y | 0.44 |
| Sharpe Ratio 12m | -0.47 |
| Alpha | -28.83 |
| Beta | 0.961 |
| Volatility | 14.47% |
| Current Volume | 14663.6k |
| Average Volume 20d | 13325.3k |
| Stop Loss | 133.7 (-3%) |
| Signal | 0.49 |
What is the price of XLV shares?
Over the past week, the price has changed by +0.34%, over one month by +4.08%, over three months by +4.09% and over the past year by -9.21%.
Is Health Care Sector SPDR Fund a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XLV is around 128.77 USD . This means that XLV is currently overvalued and has a potential downside of -6.62%.
Is XLV a buy, sell or hold?
What are the forecasts/targets for the XLV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 144.9 | 5.1% |
Last update: 2025-08-30 05:06
XLV Fundamental Data Overview
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 USD
Beta = 0.61
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 33.64b USD (33.64b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 33.64b)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 33.64b / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(33.64b)/V(0.0) * Re(9.56%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for XLV ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle